On April 2, 2026, President Trump issued two proclamations under Section 232 of the Trade Expansion Act of 1962 that make significant changes to the Section 232 tariff landscape.

The first presidential proclamation modifies existing Section 232 tariffs on steel, aluminum and copper, effective April 6, 2026 (the Metals Proclamation), and resolves key ambiguities regarding how importers should assess and apply these tariffs.

The second presidential proclamation imposes new Section 232 tariffs on patented pharmaceuticals and associated ingredients, with tariffs taking effect on July 31, 2026 for certain named companies and September 29, 2026 for all others (the Pharmaceuticals Proclamation).

Modifications to steel, aluminum and copper tariffs

The Metals Proclamation overhauls the existing Section 232 tariff framework for steel, aluminum and copper articles and related derivative products, which, since last year, have been subject to 50 percent tariffs assessed against the value of their steel, aluminum and/or copper content. The Metals Proclamation simplifies this framework by:

  1. keeping the 50 percent rate for the entire value of goods that are wholly, or almost entirely, made from steel, aluminum or copper;
  2. replacing the prior 50 percent content-based tariff with a lower flat 25 percent rate assessed against the full entered value of the imported derivatives;
  3. excluding from the tariffs any derivative products which have less than 15 percent by weight steel, aluminum or copper content; and
  4. meaningfully reducing the scope of the derivative product lists.

These modifications took effect as of 12:01 am eastern time on April 6, 2026.

Specifically, the proclamation establishes the following flat rate structure for Section 232 tariffs on steel, aluminum and copper, as detailed in the Annexes to the proclamation:

  • Articles made entirely or almost entirely of steel, aluminum or copper (as identified in Annex I-A), such as unwrought metals, bars, rods, plates, sheets, tubes and pipes, are subject to a 50 percent tariff on the full entered value of the article.

  • Derivative articles (as identified in Annex I-B) are subject to a 25 percent tariff on the full entered value of the article.

  • There are also a number of separate rates established for certain products and countries:

    • Certain metal-intensive industrial machinery and electrical grid equipment listed in Annex III to the Metals Proclamation are subject to a temporary reduced rate of 15 percent (inclusive of applicable regular customs duties) through December 31, 2027.
    • Products manufactured abroad but composed entirely of US-origin metals (at least 95 percent smelted/cast or melted/poured in the United States) are subject to a reduced 10 percent tariff.
    • UK-origin products meeting equivalent origin requirements are subject to a 25 percent rate for articles made entirely or mostly of steel, aluminum or copper (as identified in Annex I-A) and a 15 percent rate for all other derivatives products (as identified in Annex I-B).
    • Russian-origin aluminum remains subject to a 200 percent tariff.

The shift to a flat rate assessed against the full entered value of the product resolves key ambiguities that importers have faced in determining the “value” of the steel, aluminum and/or copper content in a derivative product in light of inconsistent guidance from US Customs and Border Protection (CBP) on the topic and related litigation at the Court of International Trade (CIT).

The proclamation also addresses challenges importers faced having to declare minimal steel aluminum and copper content in certain derivative imports. Under the new rules, derivative products classified outside HTSUS Chapters 72, 73, 74 and 76, will only be subject to the 25 percent tariff where the aggregate weight of steel, aluminum and/or copper (insofar as the product is on each of those derivative lists) is at least 15 percent of the total weight of the article. Products below this threshold are no longer subject to Section 232 metals tariffs.

If a product appears on multiple derivative lists, that product will only be subject to these tariffs once. For example, if a product is included on both the steel and aluminum derivative lists and meets or exceeds the weight threshold, it is subject to the applicable 25 percent rate only once.

The proclamation also removes a significant number of products from the derivative tariff lists (as detailed in Annex II), including certain food preparations, paints and coatings, cosmetics and personal care products, soaps and detergents, adhesives, pesticides and disinfectants, antifreezing preparations, fire extinguishers, motorcycles and motorcycle parts imported for manufacturing, cast iron cookware, tanks and armored fighting vehicles and various sporting goods.

The prior process where industry could submit recommendations for additions to the derivatives list has been abolished in favor of a more limited process where the Secretary of Commerce and the US Trade Representative (USTR) must jointly agree to any additions to the derivative lists.

Action items

To prepare for these changes, importers should:

  1. Review the Annexes to the Metals Proclamation to determine whether their relevant products are on the revised derivative lists.
  2. Evaluate whether any of their items can be excluded from the tariffs based on having less than 15 percent-by-weight aluminum, steel and/or copper content.
  3. Recalculate tariff exposure based on the new flat rates assessed against the full entered value of imported goods.
  4. Consult their customs brokers about implementing these changes.

New tariffs on pharmaceuticals and pharmaceutical ingredients

Under the Pharmaceuticals Proclamation, 100 percent Section 232 tariffs will be imposed on certain patented pharmaceuticals, together with their associated ingredients (that is, APIs and key starting materials). The tariffs apply to patented pharmaceutical products and related ingredients classifiable under more than 130 specified HTSUS subheadings spanning chapters 29 (organic chemicals) and 30 (pharmaceutical products), as enumerated in the Annexes to the Proclamation. For 17 named major drug companies, these tariffs will take effect on July 31, 2026 (120 days from the proclamation), and for all others, these tariffs will take effect on September 29, 2026 (180 days from the proclamation).

The key takeaways from the Pharmaceuticals Proclamation are as follows:

  • The tariffs apply to certain “patented” pharmaceuticals and their associated ingredients. "Patented pharmaceutical articles" is defined as articles that are subject to a valid, unexpired US patent and are listed in the FDA's Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or Purple Book (Lists of Licensed Biological Products), together with their associated APIs and key starting materials.

  • Generic pharmaceuticals and their associated ingredients, and biosimilar biologics applications, are excluded and not currently subject to these new Section 232 tariffs. This exclusion will be reassessed within one year.

  • Certain specialty products, including orphan drugs, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies and medical countermeasures, are subject to a zero tariff rate, subject to determinations by the Secretary of Commerce in consultation with USTR and HHS.

  • US-origin pharmaceutical products are also excluded.

  • While the default rate is 100 percent, a number of reduced rates are available:

    • Companies with Secretary-approved onshoring plans are eligible for a reduced rate of 20 percent, rising to 100 percent on April 2, 2030.
    • Companies with both an onshoring plan and an MFN pricing agreement with HHS are eligible for a reduced rate of 0 percent until January 20, 2029.
    • Products of Japan, the EU, South Korea, Switzerland and Liechtenstein are subject to a reduced rate of 15 percent, unless a lower rate applies.
    • Products of the UK are subject to a reduced rate of 10 percent, which may be reduced to zero under a bilateral pharmaceutical pricing agreement.

Action items

To prepare for these new tariffs, importers should:

  1. Determine whether imported products qualify as "patented pharmaceutical articles" or are excluded as generics or biosimilars.
  2. Review the Annexes to the Pharmaceuticals Proclamation to identify the applicable rates under these new tariffs.
  3. Assess eligibility for reduced rates based on country of origin, onshoring plans or MFN pricing agreements.
  4. For companies not yet party to any such agreements, evaluate whether to pursue an onshoring plan and/or MFN pricing agreement.

If you have questions about how these new tariffs may affect your operations, please reach out to our team. We will continue to monitor developments and provide updates as additional guidance and CBP implementation instructions are issued.

card-grid-item, aem-sourced
Navigating international trade
and tariffs

Impacts of evolving trade regulations and compliance risks

/en/insights/publications/navigating-international-trade-and-tariffs

Contact